Back to results
US 7,608,263 B2Granted
RG1 antibodies and uses thereof
AssigneeBayer Schering Pharma Aktiengesellschaft
InventorsRichard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
Life of this patent
Estimating the term…
Abstract
The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
Claims10
A method for selectively destroying a cell expressing a human RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2, which method comprises reacting an effective amount of an immunoconjugate with the cell wherein
- (i) the immunoconjugate comprises an isolated antibody or a fragment thereof that binds to RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2, conjugated to a therapeutic agent, and
- (ii) the isolated antibody or a fragment thereof comprises
- a) a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 26 or SEQ ID NO:
- 29, or
- b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 30, or SEQ ID NO:
- 31 or
- c) a light chain variable region having the amino acid sequence of SEQ ID NO:
- 26 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 27 or SEQ ID NO:
- 28, or
- d) a light chain variable region having the amino acid sequence of SEQ ID NO:
- 29 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 30 or SEQ ID NO:
- 31,
- thereby selectively destroying the cells expressing human RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2.
19 more elements
A method for selectively destroying a cell expressing a human RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2, which method comprises reacting the cell with an effective amount of an immunoconjugate, wherein
- (i) the immunoconjugate comprises an isolated antibody or a fragment thereof, that binds to RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2, conjugated to a therapeutic agent and
- (ii) the isolated antibody or a fragment thereof comprises:
- a) a light chain CDR3 sequence comprising the amino acid residues 110 to 117 of SEQ ID NO:
- 26,
- b) a heavy chain CDR3 sequence comprising the amino acid residues 117 to 132 of SEQ ID NO:
- 27,
- c) a light chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 44 to 55 of SEQ ID NO:
- 26 and 71 to 77 of SEQ ID NO:
- 26, respectively, and
- d) a heavy chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 50 to 54 of SEQ ID NO:
- 27 and 69 to 84 of SEQ ID NO:
- 27, respectively,
- thereby selectively destroy the cell expressing human RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2.
13 more elements
A method for selectively destroying a cell expressing a human RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2, which method comprises reacting the cell with an effective amount of an immunoconjugate, wherein
- (i) the immunoconjugate comprises an isolated antibody or a fragment thereof, that binds to RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2, conjugated to a therapeutic agent, and
- (ii) the isolated antibody or a fragment thereof comprises:
- a) a light chain CDR3 sequence comprising the amino acid residues 110 to 117 of SEQ ID NO:
- 29,
- b) a heavy chain CDR3 sequence comprising the amino acid residues 117 to 126 of SEQ ID NO:
- 30,
- c) a light chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 44 to 55 of SEQ ID NO:
- 29 and 71 to 77 of SEQ ID NO:
- 29, respectively, and
- d) a heavy chain CDR1 sequence and CDR2 sequence, wherein the sequences comprise the amino acid residues 50 to 54 of SEQ ID NO:
- 30 and 69 to 84 of SEQ ID NO:
- 30, respectively,
- thereby selectively destroy the cell expressing human RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2.
13 more elements
A method for inhibiting a cell expressing a human RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2, which method comprises reacting an effective amount of an antibody with the cell, wherein the antibody comprises:
- (i) a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 26 or SEQ ID NO:
- 29,
- (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 27, SEQ ID NO:
- 28, SEQ ID NO:
- 30, or SEQ ID NO:
- 31,
- (iii) a light chain variable region having the amino acid sequence of SEQ ID NO:
- 26 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 27 or SEQ ID NO:
- 28,
- (iv) a light chain variable region having the amino acid sequence of SEQ ID NO:
- 29 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:
- 30 or SEQ ID NO:
- 31,
- (v) a light chain CDR3 sequence comprising the amino acid residues 110 to 117 of SEQ ID NO:
- 26 a heavy chain CDR3 sequence comprising the amino acid residues 117 to 132 of SEQ ID NO:
- 30, a light chain CDR1 sequence and CDR2 sequence wherein the sequences comprise the amino acid residues 44 to 55 of SEQ ID NO:
- 26 and 71 to 77 of SEQ ID NO:
- 26 respectively, and a heavy chain CDR1 sequence and CDR2 sequence wherein the sequences comprise the amino acid residues 50 to 54 of SEQ ID NO:
- 27 and 69 to 84 of SEQ ID NO:
- 27, respectively, or
- (vi) a light chain CDR3 sequence comprising the amino acid residues 110 to 117 of SEQ ID NO:
- 29, a heavy chain CDR3 sequence comprising the amino acid residues 117 to 126 of SEQ ID NO:
- 30, a light chain CDR1 sequence and CDR2 sequence wherein the sequences comprise the amino acid residues 44 to 55 of SEQ ID NO:
- 29 and 71 to 77 of SEQ ID NO:
- 29, respectively, and a heavy chain CDR1 sequence and CDR2 sequence wherein the sequences comprise the amino acid residues 50 to 54 of SEQ ID NO:
- 30 and 69 to 84 of SEQ ID NO:
- 30, respectively,
- thereby inhibiting the cell expressing the human RG1 polypeptide having the amino acid sequence of SEQ ID NO:
- 2.
30 more elements
Dependencies are inferred from the claim text.